Cite
Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial.
MLA
Nakachi, Kohei, et al. “Adjuvant S-1 Compared with Observation in Resected Biliary Tract Cancer (JCOG1202, ASCOT): A Multicentre, Open-Label, Randomised, Controlled, Phase 3 Trial.” Lancet, vol. 401, no. 10372, Jan. 2023, pp. 195–203. EBSCOhost, https://doi.org/10.1016/S0140-6736(22)02038-4.
APA
Nakachi, K., Ikeda, M., Konishi, M., Nomura, S., Katayama, H., Kataoka, T., Todaka, A., Yanagimoto, H., Morinaga, S., Kobayashi, S., Shimada, K., Takahashi, Y., Nakagohri, T., Gotoh, K., Kamata, K., Shimizu, Y., Ueno, M., Ishii, H., Okusaka, T., & Furuse, J. (2023). Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet, 401(10372), 195–203. https://doi.org/10.1016/S0140-6736(22)02038-4
Chicago
Nakachi, Kohei, Masafumi Ikeda, Masaru Konishi, Shogo Nomura, Hiroshi Katayama, Tomoko Kataoka, Akiko Todaka, et al. 2023. “Adjuvant S-1 Compared with Observation in Resected Biliary Tract Cancer (JCOG1202, ASCOT): A Multicentre, Open-Label, Randomised, Controlled, Phase 3 Trial.” Lancet 401 (10372): 195–203. doi:10.1016/S0140-6736(22)02038-4.